XOMA (NASDAQ:XOMA) announced its quarterly earnings results on Tuesday. The biotechnology company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.07, Bloomberg Earnings reports. XOMA had a negative return on equity of 51.66% and a negative net margin of 48.62%. The company had revenue of $0.96 million for the quarter, compared to the consensus estimate of $0.63 million.
Shares of XOMA stock traded up $0.22 during midday trading on Wednesday, hitting $16.21. The company had a trading volume of 448 shares, compared to its average volume of 72,217. The company’s 50 day moving average price is $17.17. The company has a market cap of $136.21 million, a PE ratio of -10.18 and a beta of 1.29. The company has a current ratio of 7.20, a quick ratio of 7.20 and a debt-to-equity ratio of 1.13. XOMA has a 1-year low of $11.02 and a 1-year high of $24.66.
In related news, major shareholder Bvf Partners L. P/Il acquired 10,300 shares of the stock in a transaction dated Friday, May 10th. The shares were acquired at an average price of $14.57 per share, for a total transaction of $150,071.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Bvf Partners L. P/Il acquired 3,797 shares of the stock in a transaction dated Monday, May 13th. The stock was bought at an average price of $14.36 per share, for a total transaction of $54,524.92. The disclosure for this purchase can be found here. In the last 90 days, insiders bought 42,010 shares of company stock worth $612,963. 9.89% of the stock is currently owned by corporate insiders.
XOMA Company Profile
XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy.
Further Reading: What is an Initial Public Offering (IPO)?
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.